Healio Rheumatology reports on the first interchangeable biosimilar approved by the U.S. Food and Drug Administration (FDA) to treat certain inflammatory diseases and includes perspective from David R. Fernandez, MD, PhD, rheumatologist at HSS.

According to Dr. Fernandez, “I think overall public interest in biosimilars will be impacted in a big way if use of biosimilars results in cost savings or ease of authorization that are felt at the level of the individual patient or prescriber – failing that, enthusiasm may remain limited.”

Read the full article at Healio.com/news/rheumatology.